Sanofi and Regeneron have scored big with the IL4/IL13 pathway, which has proved to be a blockbuster approach for their drug Dupixent (dupilumab). But Sanofi’s solo effort on a similar pathway approach for SAR156597 proved to be a flop.
The French pharma outfit noted in their Q3 release this morning that they are scrapping a mid-stage program for the IL4/13 drug SAR156597 in idiopathic pulmonary fibrosis, a lung scarring disease. There was no word on the reason why.
Just a few weeks ago, though, Regeneron chief scientist George Yancopoulos was touting the longterm potential for the pathway as he reviewed the promising Phase III asthma results for Dupixent. His comment:
These results continue to support our hypothesis that the IL4/IL13 pathway is a critical driver of allergic disease, and we remain committed to further investigating the IL-4/IL-13 pathway in other allergic diseases.
IL-13, though, has proven to be a bitter disappointment for the anti-inflammatory sector. AstraZeneca’s tralokinumab flunked three straight Phase III studies for asthma, while Roche auctioned off lebrikizumab after seeing mixed late-stage data.
Sanofi is stepping back from its big antibody collaboration with Regeneron at the end of this year, determined to stand on its own two feet. Their in-house R&D track record over the past decade, though, has been awful.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 33,200+ biopharma pros who read Endpoints News by email every day.Free Subscription